Inovio Product Pipeline
Inovio is focused on the discovery, development and delivery of an important new generation of vaccines, called DNA vaccines. The ability of DNA vaccines to induce not only a strong antibody response but also a strong T-cell response creates the potential to prevent and treat cancers and chronic infectious diseases. Furthermore, the capabilities of genomic engineering enables the design of optimized vaccines that may protect against a broad spectrum of evolving strains of a pathogen, such as influenza, that is not specifically matched to the genetic make-up of the vaccine.
Inovio's novel SynCon™ DNA vaccine construct technology and electroporation DNA delivery technology have enabled the development of an active pipeline of proprietary preclinical and clinical DNA vaccines, as shown below. Multiple partners and collaborators are also using Inovio's electroporation technology under license to facilitate their DNA vaccine research. These programs are described in the following sections under the categories of cancers and infectious diseases.
Inovio has conducted early research to assess the potential utility of electroporation-delivered DNA vaccines for a range of diseases. These programs help to characterize the potential applicability and importance of DNA vaccines and may be the focus of additional future R&D effort. Various collaborators are also funding and conducting research using Inovio's electroporation-based DNA delivery systems in conjunction with experimental vaccines for different diseases.
Inovio has a non-vaccine, small molecule drug under development that is focused on inflammatory diseases including rheumatoid arthritis (RA), Type 1 diabetes (T1D), uveitis, and colitis.
The company owns a majority interest in VGX Animal Health, Inc., which markets LifeTide™ animal growth hormone for swine. LifeTide™ is one of only four DNA-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia).
